XBiotech Inc.
XBITHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, XBiotech Inc. focuses on Biotechnology services and products. XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. The $68.3M market capitalization puts XBIT squarely in micro-cap range for its industry. It develops a pipeline of product candidates targeting inflammatory and infectious diseases.
Market Cap
$68.3M
Beta
0.84
P/E (TTM)
—
P/E (Fwd)
17.23
EPS (TTM)
$-1.30
EPS (Fwd)
$0.13
ROE
-25.9%
ROA
-18.8%
Cash
$115.5M
Total Debt
$0
Free CF
-$30.6M
52W Change
-27.3%
Annual Financials
Cash vs Debt
Where XBIT stands vs its 150-day and 200-day moving averages
As of the July 9, 2026 close, XBIT finished 2.48% below its 150-day moving average ($2.42) and 3.28% below its 200-day moving average ($2.44). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is XBIT overbought or oversold?
At the July 9, 2026 close, XBIT's RSI(14) was 51.6, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
XBiotech Inc. reports $115.5M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$30.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -25.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $4.0M (2022) to $0 (2025), a 100% decline worth watching.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing XBIT.